Inactive Instrument

News Transcept Pharmaceuticals Inc Nasdaq

Equities

US89354M1062

End-of-day quote Nasdaq Other stock markets
- ^USD	-

Mar. 05	Paratek Pharmaceuticals Announces Positive Efficacy Data for Nuzyra® as Post-Exposure Prophylaxis of Inhalational Anthrax, Triggering Additional Procurement Under Barda Project Bioshield Contract	CI
Jan. 16	Paratek Pharmaceuticals, Inc. Promotes Jonathan Light to General Counsel, Corporate Secretary and Chief Compliance Officer	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Paratek Pharmaceuticals Announces Positive Efficacy Data for Nuzyra® as Post-Exposure Prophylaxis of Inhalational Anthrax, Triggering Additional Procurement Under Barda Project Bioshield Contract	Mar. 05	CI
Paratek Pharmaceuticals, Inc. Promotes Jonathan Light to General Counsel, Corporate Secretary and Chief Compliance Officer	Jan. 16	CI
Paratek Pharmaceuticals, Inc. Promotes Christopher Bostrom to Chief Financial Officer	Jan. 16	CI
Healthcare & Life Sciences Private Equity Deal Tracker: Gurnet Point And Novo Holdings Acquire Paratek Pharmaceuticals	23-10-05	AQ
Paratek Pharmaceuticals to Present NUZYRA Data at IDWeek 2023	23-10-05	AQ
Novo Holdings, Gurnet Point Close $462 Million Purchase of Paratek Pharmaceuticals	23-09-22	MT
Novo Holdings closes $462 million acquisition of Paratek Pharmaceuticals	23-09-21	RE
Paratek Pharmaceuticals, Inc. Announces Board Changes	23-09-21	CI
Gurnet Point Capital and Novo Holdings A/S Complete Acquisition of Paratek Pharmaceuticals, Inc.	23-09-21	AQ
Paratek Pharmaceuticals, Inc.(NasdaqGM:PRTK) dropped from NASDAQ Composite Index	23-09-21	CI
Paratek Pharmaceuticals, Inc.(NasdaqGM:PRTK) dropped from S&P Global BMI Index	23-09-21	CI
Paratek Pharmaceuticals, Inc.(NasdaqGM:PRTK) dropped from S&P TMI Index	23-09-21	CI
Gurnet Point Capital Limited and Novo Holdings A/S acquired acquire Paratek Pharmaceuticals, Inc. from a group of shareholders.	23-09-20	CI
Paratek Pharmaceuticals Says Shareholders Approved $462 Million Acquisition by Gurnet Point Capital, Novo Holdings	23-09-18	MT
Paratek Pharmaceuticals Announces Stockholder Approval of Acquisition by Gurnet Point Capital and Novo Holdings A/S	23-09-18	AQ
Second Leading Independent Proxy Advisory Firm Glass Lewis Recommends Paratek Pharmaceuticals Stockholders Vote FOR the Acquisition by Gurnet Point Capital and Novo Holdings A/S	23-09-12	AQ
Leading Independent Proxy Advisory Firm ISS Recommends Paratek Pharmaceuticals Stockholders Vote FOR the Acquisition by Gurnet Point Capital and Novo Holdings	23-09-07	GL
Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Acquisition of Paratek Pharmaceuticals, Inc. by Gurnet Point Capital	23-08-22	PR
Investor Alert: Abbott Cooper PLLC Announces Investigation into Paratek Pharmaceuticals, Inc.; Urges Paratek Stockholders to Contact Abbott Cooper Regarding Their Legal Rights	23-08-09	BU
Paratek Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-03	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Transcept Pharmaceuticals Inc Nasdaq

Equities

US89354M1062

Summary

Filters